SOURCE: RoboticOncology.com

prostate cancer - www.roboticoncology.com

August 03, 2009 15:47 ET

Prostate Cancer Surgeon David B. Samadi, MD Discusses Importance of Surgical Experience in Robotic Surgery on Channel 12 TV

NEW YORK, NY--(Marketwire - August 3, 2009) - Dr. David B. Samadi, one of the nation's leading urologic oncologists, appeared on Cablevision's 12 on Health to discuss the importance of surgical experience in robotic prostatectomy, a minimally invasive type of prostate cancer treatment that utilizes a robotic surgical unit called the da Vinci system. This prostate surgery is a revolutionary and advanced procedure that profoundly reduces blood loss, pain, recovery time, hospital stays, trauma to surrounding tissue and side effects of other treatments such as incontinence and sexual dysfunction. However, each patient is different, and in the rare cases where open or laparoscopic is needed to complete robotic surgery, doctors with expertise in all three areas are best equipped to bring about successful patient outcomes.

Dr. Samadi, the Chief of the Division of Robotics and Minimally Invasive Surgery in the Department of Urology at The Mount Sinai Medical Center in New York City, is one of very few urologic oncologic surgeons in the United States who is trained in all three primary areas of surgery: open, laparoscopic, and robotic. He has achieved great success treating more than 2,000 prostate cancer patients from around the world. His vast da vinci surgery experience accounts for the successful treatment of prostate cancer, as well as other conditions.

In robotic surgery, the surgeon performs the procedure at a console 10 feet away from the patient. From the console, the surgeon's movements are communicated to the tip of robotic hands. With the use of the da Vinci robot, robotic prostatectomy patients not only have an excellent cure rate, but also less blood loss and need for transfusions. In addition, hospital stays are shorter with less chance of infection. Most importantly, the neurovascular bundle responsible for continence and sexual function is spared in this type of procedure. About 80-85 percent of Dr. Samadi's patients return to full potency at one year and another 90-95 percent regain continence at one year. This translates into better quality of life.

As part of his urologic oncology practice at The Mount Sinai Medical Center, Dr. Samadi uses the da Vinci robot for the treatment and removal of bladder (cystectomy) and kidney (nephrectomy) cancers as well. Since the learning curve for robotic surgery is so steep, Dr. Samadi firmly believes that having the versatility of experience is the key to successful prostate, bladder, and kidney cancer surgeries.

If you would like more information about Dr. Samadi's state-of-the-art urologic oncology expertise, including the robotic prostatectomy, robotic nephrectomy, or robotic cystectomy, please don't hesitate to call him at 1-888-Robot10 (1-888-762-6810), or visit him on the web at www.roboticoncology.com.